Arthritis, Rheumatoid
Conditions
Interventions
The methodology used will be a double-blind randomized controlled clinical trial, which will be developed in two stages. In the first stage, a pilot study will be carried out lasting four months and w
E02.190.204
Sponsors
Universidade Federal de Sergipe
Universidade Federal de Sergipe
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients previously diagnosed with rheumatoid arthritis and/or fibromyalgia, according to the diagnostic criteria of the American College of Rheumatology. Patients of both gender. Aged over 18 years. Who have been using pharmacotherapy prescribed for rheumatoid arthritis for at least 6 months, and/or pharmacotherapy prescribed for fibromyalgia for at least 1 month
Exclusion criteria
Exclusion criteria: Patients with severe psychiatric disorders; cancer; pregnant women; those participating in other clinical trials that have the same outcomes or interventions that may cause a risk of bias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes evaluated will be quality of life and pain intensity. To assess health-related quality of life (HRQoL), the Portuguese version of the European quality of life scale (EQ-5D) will be used. To assess pain intensity, the visual analogue scale (VAS) will be used. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will be adherence to pharmacotherapy, patient satisfaction and medication-related problems. To assess adherence to pharmacotherapy, an adaptation of the four-item Therapeutic Adherence Scale will be used. To carry out the assessment of drug-related problems (DRP), the four-item classification will be used. To assess patient satisfaction, the Net Promoter Score (NPS) method will be used. | — |
Countries
Brazil
Contacts
Public ContactAlana Costa
Universidade Federal de Sergipe
Outcome results
None listed